1604, 2020
A new therapeutic opportunity treatment of NSCLC: the BRAF V600 mutation
FDA and EMA approved and reimbursed dabrafenib + trametinib combination [...]
FDA and EMA approved and reimbursed dabrafenib + trametinib combination [...]